Charles Bennett to Leukoencephalopathy, Progressive Multifocal
This is a "connection" page, showing publications Charles Bennett has written about Leukoencephalopathy, Progressive Multifocal.
Connection Strength
4.717
-
Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update. Cancer Treat Res. 2022; 184:103-111.
Score: 0.752
-
Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021 Aug; 8(8):e593-e604.
Score: 0.731
-
Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
Score: 0.522
-
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016 Aug; 15(8):1003-11.
Score: 0.513
-
Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Cancer. 2014 Dec 15; 120(24):4006-7.
Score: 0.451
-
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014 Aug 15; 120(16):2464-71.
Score: 0.441
-
Pharmacovigilance and PML in the oncology setting. Cleve Clin J Med. 2011 Nov; 78 Suppl 2:S13-7.
Score: 0.372
-
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 Aug; 10(8):816-24.
Score: 0.318
-
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40.
Score: 0.309
-
Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma. 2009 Mar; 50(3):323-4.
Score: 0.309